Role of oral agents in improving cardiovascular prognosis in diabetes mellitus

Mayo Clinic Proceedings

Volumn 85, Issue 1, 2010, Pages 99-

  Hirsch, Ronald Lauren ^a  

^a Signature Medical Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLYCOSIDASE INHIBITOR; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; LETTER; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

EID: 73649129242     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2009.0490     Document Type: Letter

References (2)

1. O'Keefe JH, Carter MD, Lavie CJ. Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc. 2009;84(8):741-757.
2. Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes [published corrections appear in N Engl J Med. 2009;361(10):1024-1025 and 2009;361(10):1028]. N Engl J Med. 2009 Jan 8;360(2):129-139. Epub 2008 Dec 17.